Bio Essence Files Draft Information Statement
Bitget2026/10/21 14:42- Bio Essence shareholders authorized an articles amendment granting each preferred share 10,000 votes, compared with one vote per common share.
- Shareholders holding 34,396,000 common shares, representing 63.93% of outstanding common stock on October 19, 2026, backed the amendment.
- No preferred shares are currently outstanding; future holders would receive supervoting rights.
- The amendment would enable future preferred stock issuance to maintain or transfer control without diluting common stock holdings.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
